ZA200108409B - Estrogen receptor-beta ligands. - Google Patents

Estrogen receptor-beta ligands.

Info

Publication number
ZA200108409B
ZA200108409B ZA200108409A ZA200108409A ZA200108409B ZA 200108409 B ZA200108409 B ZA 200108409B ZA 200108409 A ZA200108409 A ZA 200108409A ZA 200108409 A ZA200108409 A ZA 200108409A ZA 200108409 B ZA200108409 B ZA 200108409B
Authority
ZA
South Africa
Prior art keywords
estrogen receptor
beta ligands
ligands
beta
estrogen
Prior art date
Application number
ZA200108409A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Timothy Martin Piser
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200108409B publication Critical patent/ZA200108409B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200108409A 1999-04-16 2001-10-12 Estrogen receptor-beta ligands. ZA200108409B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12990199P 1999-04-16 1999-04-16

Publications (1)

Publication Number Publication Date
ZA200108409B true ZA200108409B (en) 2003-03-26

Family

ID=22442124

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108409A ZA200108409B (en) 1999-04-16 2001-10-12 Estrogen receptor-beta ligands.

Country Status (22)

Country Link
US (1) US6518301B1 (et)
EP (1) EP1173164A2 (et)
JP (1) JP2002542187A (et)
KR (1) KR20010108509A (et)
CN (1) CN1358091A (et)
AR (1) AR043085A1 (et)
AU (1) AU4128800A (et)
BG (1) BG106103A (et)
BR (1) BR0009814A (et)
CA (1) CA2370126A1 (et)
CZ (1) CZ20013714A3 (et)
EE (1) EE200100526A (et)
HU (1) HUP0200740A3 (et)
IL (1) IL145839A0 (et)
IS (1) IS6108A (et)
MX (1) MXPA01010423A (et)
NO (1) NO20015015L (et)
PL (1) PL351314A1 (et)
SK (1) SK14762001A3 (et)
TR (2) TR200201762T2 (et)
WO (1) WO2000062765A2 (et)
ZA (1) ZA200108409B (et)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
JP2004510815A (ja) * 2000-10-13 2004-04-08 アストラゼネカ・アクチエボラーグ エストロゲン受容体−βリガンド
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
EP1341768A1 (en) * 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
US6559177B2 (en) 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
WO2003044006A1 (en) 2001-11-19 2003-05-30 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7235539B2 (en) 2002-01-23 2007-06-26 Wyeth 6-Hydroxyequilenins as estrogenic agents
WO2003074044A1 (en) * 2002-03-01 2003-09-12 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US20050245492A1 (en) * 2004-04-28 2005-11-03 Lephart Edwin D Use of equol for treating skin diseases
US7468445B2 (en) 2002-08-07 2008-12-23 University Of Mississippi Antigiardial agents and use thereof
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
SI1626974T1 (sl) * 2003-04-21 2009-02-28 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
MX2007002251A (es) * 2004-08-26 2007-04-20 Wyeth Corp Benzoxazoles sustituidos con profarmaco como agentes estrogenicos.
WO2006029146A2 (en) 2004-09-07 2006-03-16 Wyeth 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
BRPI0519111A2 (pt) * 2004-12-17 2008-12-23 Wyeth Corp mÉtodos para tratar o mal de parkinson, para melhorar um sintoma do mal de parkinson e para melhorar um sintoma de uma doenÇa ou distérbio cognitivos, e, uso de um ligando seletivo de erbeta
WO2006088716A1 (en) * 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
EP2526941A1 (en) * 2005-03-24 2012-11-28 Marshall Edwards, Inc. Anti-inflammatory Modalities
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
CN102702013B (zh) * 2005-11-28 2016-02-10 Gtx公司 核受体结合剂
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
KR101646804B1 (ko) * 2008-10-29 2016-08-08 메르크 파텐트 게엠베하 액정 디스플레이
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
ES2343347B2 (es) * 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CN101863867B (zh) * 2009-04-14 2012-07-18 清华大学深圳研究生院 黄酮类化合物的衍生物及其制备方法与应用
EP2705047B1 (en) * 2011-04-25 2015-08-05 Council of Scientific & Industrial Research Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
CN103450134B (zh) * 2012-05-31 2017-12-22 中国医学科学院药物研究所 香豆素衍生物的制备及其在防治脑部重大疾病中的应用
US9718799B2 (en) 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
EP3597187A1 (en) * 2018-07-16 2020-01-22 Centre National De La Recherche Scientifique Brag2 inhibitors and applications thereof
CN112574177B (zh) * 2020-12-21 2023-01-31 陕西师范大学 一类嘧啶衍生物及其制备抗肿瘤药物的应用
CN115322198A (zh) * 2022-06-13 2022-11-11 上海工程技术大学 基于喹诺里西啶类衍生物的药物化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954371A (et) * 1972-09-28 1974-05-27
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
JPS6048924A (ja) 1983-08-24 1985-03-16 Takeda Chem Ind Ltd 骨粗鬆症治療剤
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
JP3085464B2 (ja) * 1990-05-24 2000-09-11 コニカ株式会社 感熱拡散転写材料
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
JPH05112552A (ja) * 1991-10-17 1993-05-07 Tanabe Seiyaku Co Ltd ベンゾピラン誘導体及びその製法
JP3166093B2 (ja) * 1993-08-13 2001-05-14 森永乳業株式会社 クマリン誘導体及びそれらの用途
JPH06321752A (ja) * 1993-05-07 1994-11-22 Kao Corp 美白剤
JP3522754B2 (ja) * 1993-12-16 2004-04-26 マリンクロッド・インコーポレイテッド 多価フェノール化合物類
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
GB9707013D0 (en) 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
CA2287965C (en) 1997-05-01 2009-10-20 Graham Edmund Kelly Treatment or prevention of menopausal symptoms and osteoporosis

Also Published As

Publication number Publication date
NO20015015D0 (no) 2001-10-15
CA2370126A1 (en) 2000-10-26
EE200100526A (et) 2002-12-16
SK14762001A3 (sk) 2002-10-08
CZ20013714A3 (cs) 2002-08-14
AR043085A1 (es) 2005-07-20
NO20015015L (no) 2001-12-17
TR200102992T2 (tr) 2004-12-21
US6518301B1 (en) 2003-02-11
CN1358091A (zh) 2002-07-10
EP1173164A2 (en) 2002-01-23
IS6108A (is) 2001-10-15
BG106103A (en) 2002-05-31
KR20010108509A (ko) 2001-12-07
HUP0200740A2 (hu) 2002-07-29
TR200201762T2 (tr) 2002-10-21
WO2000062765A3 (en) 2001-09-07
WO2000062765A2 (en) 2000-10-26
MXPA01010423A (es) 2002-03-27
JP2002542187A (ja) 2002-12-10
AU4128800A (en) 2000-11-02
PL351314A1 (en) 2003-04-07
HUP0200740A3 (en) 2004-08-30
BR0009814A (pt) 2002-01-08
IL145839A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
ZA200108409B (en) Estrogen receptor-beta ligands.
ZA200107411B (en) Melanocortin receptor ligands.
HK1053050A1 (en) Bra.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200005428B (en) Standard peripheral communication.
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1054910A1 (en) Micromachines.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
AU1199600A (en) Estrogen receptor ligands
MXPA03002691A (es) Ligandos de receptor de melanocortina.
ZA200005136B (en) Dihydropyrimides.
ZA200202537B (en) Pour-on-formulations.
HK1051199A1 (en) New phenylpiperazines.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
HK1029502A1 (en) Slider-pull-assembling unit.
MXPA02005103A (es) Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
ZA992443B (en) Hydroxy-methyl-hexanones.
AU2001296119A1 (en) Estrogen receptor-beta ligands
ZA993064B (en) Hygromycin a derivatives.
GB0012054D0 (en) Ligands
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA993123B (en) Trisresorcinyltriazines.
MXPA02000261A (es) Aminoindanos novedosos.
ZA992018B (en) Banners.
GB9828192D0 (en) Macro-complexed ligand binders